Investor Relations

Esperion Therapeutics, Inc. is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 4:00 PM ET on Mar 26, 2015
Last Price Change Open Day High 52-Week High
88.50
1.27  up   (1.456%) 85.33 92.75 118.95
Volume Previous Close Day Low 52-Week Low
2,022,500 87.23 84.25 12.75

View all »   RSSRecent Releases

Mar 24, 2015
Esperion Therapeutics Announces Closing of Follow-On Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock

Mar 18, 2015
Esperion Therapeutics Prices Public Offering of Common Stock